Brief: Grace Therapeutics Announces Submission Of New Drug Application To US FDA For Gtx-104
June 25 (Reuters) - Grace Therapeutics, Inc GRCE.O: GRACE THERAPEUTICS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR GTX-104 GRACE THERAPEUTICS- NDA SUBMISSION INCLUDES POSITIVE DATA FROM PHASE 3 STRIVE-ON TRIAL Source text: ID:nGNXbN5SCn Further company coverage: GRCE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grace Therapeutics
See all newsBrief: Grace Therapeutics - Selling Stockholders May Resell Up To 4,761,904 Shares Of Common Stock - SEC Filing
Grace Therapeutics Q1 net loss widens on impairment charges
Grace Therapeutics falls after FDA declines to approve stroke drug
NASDAQ RESUMED AT 01:57 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:52 PM